CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS BLOOD SCREENING HIV PROBE LICENSE AGREEMENT— EUROPEAN UNION between CHIRON...Hiv Probe License Agreement • August 12th, 2003 • Chiron Corp • Pharmaceutical preparations
This agreement (hereinafter "Agreement") is made by and between CHIRON CORPORATION, a Delaware corporation, of 4560 Horton Street, Emeryville, California 94608 (hereinafter referred to as "CHIRON"), F. HOFFMANN-LA ROCHE LTD., a Swiss corporation, of Grenzacherstrasse 124, Basel, Switzerland (hereinafter referred to as "ROCHE PARENT"), and ROCHE MOLECULAR SYSTEMS, INC., a Delaware corporation, of 1145 Atlantic Avenue, Suite 100, Alameda, California 94501 (hereinafter referred to as "RMS" and collectively with ROCHE PARENT, "ROCHE").
TERM SHEETHiv Probe License Agreement • November 2nd, 2004 • Chiron Corp • Pharmaceutical preparations
This binding Term Sheet sets forth the agreement of Chiron Corporation ("Chiron"), on the one hand, and F. Hoffmann-La Roche Ltd. and Roche Molecular Systems, Inc. (collectively, "Roche"), on the other, with respect to the settlement of their current arbitration relating to royalties ("Arbitration"), through amendment of the HIV Probe License Agreement by and between the parties effective as of October 10, 2000 ("Clinical Diagnostics Agreement") and the Blood Screening HIV Probe License Agreement by and between the parties effective as of January 1, 2001 ("Blood Screening Agreement," collectively with the Clinical Diagnostics Agreement, the "Agreements"). Terms not defined in this Term Sheet have the meanings given to them in the applicable Agreement. This Term Sheet shall become effective as of September 3, 2004.
BETWEENHiv Probe License Agreement • November 7th, 2000 • Chiron Corp • Pharmaceutical preparations
TERM SHEETHiv Probe License Agreement • December 16th, 2004 • Chiron Corp • Pharmaceutical preparations
This binding Term Sheet sets forth the agreement of Chiron Corporation ("Chiron"), on the one hand, and F. Hoffmann-La Roche Ltd. and Roche Molecular Systems, Inc. (collectively, "Roche"), on the other, with respect to the settlement of their current arbitration relating to royalties ("Arbitration"), through amendment of the HIV Probe License Agreement by and between the parties effective as of October 10, 2000 ("Clinical Diagnostics Agreement") and the Blood Screening HIV Probe License Agreement by and between the parties effective as of January 1, 2001 ("Blood Screening Agreement," collectively with the Clinical Diagnostics Agreement, the "Agreements"). Terms not defined in this Term Sheet have the meanings given to them in the applicable Agreement. This Term Sheet shall become effective as of September 3, 2004.
